Compare ATOM & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATOM | CHRS |
|---|---|---|
| Founded | 2001 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 157.7M | 177.7M |
| IPO Year | 2016 | 2014 |
| Metric | ATOM | CHRS |
|---|---|---|
| Price | $4.28 | $1.15 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.51 |
| AVG Volume (30 Days) | 404.0K | ★ 1.1M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 4.41 | ★ 472.00 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $62,000.00 | N/A |
| Revenue This Year | $527.69 | $73.08 |
| Revenue Next Year | N/A | $30.94 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.89 | $1.09 |
| 52 Week High | $12.37 | $2.62 |
| Indicator | ATOM | CHRS |
|---|---|---|
| Relative Strength Index (RSI) | 46.93 | 38.06 |
| Support Level | $4.19 | N/A |
| Resistance Level | $5.06 | $1.53 |
| Average True Range (ATR) | 0.20 | 0.09 |
| MACD | 0.10 | -0.02 |
| Stochastic Oscillator | 75.34 | 1.72 |
Atomera Inc is engaged in the business of developing, commercializing, and licensing proprietary processes and technologies for the semiconductor industry. The company's technology, named Mears Silicon Technology, or MST, is a thin film of re-engineered silicon, typically 100 to 300 angstroms (or approximately 20 to 60 silicon atomic unit cells) thick. MST can be applied as a transistor channel enhancement to CMOS-type transistors, the majority of widely used in the semiconductor industry. The company's silicon technology can be used for applications like Analog, DRAM, logic, processors, and SRAM. Geographically, it generates maximum revenue from North America.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.